2 enrolling by invitation. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) Lunsekimig - Chronic Obstructive Pulmonary Disease | Phase 3 | Enrolling by invitation | Sanofi | 1508 | 2026-09-16 | 2026-10-21 |
| Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency Alpha-1 MP - Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Phase 3 | Enrolling by invitation | Grifols Therapeutics LLC | 290 | 2016-07-01 | 2026-06-23 |
Pulmonary Emphysema (1) · alpha 1-Antitrypsin Deficiency (1)
Chronic Disease (2) · Disease Attributes (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Emphysema (1) · Genetic Diseases, Inborn (1) · Liver Diseases (1) · Subcutaneous Emphysema (1)
Grifols Therapeutics LLC (1) · Sanofi (1)
Canada (2) · United States (2) · Australia (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1) · Moldova (1) · New Zealand (1) · Poland (1) · Russia (1) · Sweden (1) · United Kingdom (1)